Incyte Stock Price, News & Analysis (NASDAQ:INCY)

$95.97 -2.13 (-2.17 %)
(As of 12/15/2017 07:07 AM ET)
Previous Close$98.10
Today's Range$95.86 - $99.50
52-Week Range$92.91 - $153.15
Volume1.30 million shs
Average Volume1.90 million shs
Market Capitalization$20.70 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.74

About Incyte (NASDAQ:INCY)

Incyte logoIncyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700

Debt

Debt-to-Equity Ratio0.01%
Current Ratio4.82%
Quick Ratio4.81%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.11 billion
Price / Sales18.32
Cash Flow$0.91 per share
Price / Cash104.95
Book Value$2.23 per share
Price / Book43.04

Profitability

Trailing EPS($0.80)
Net Income$104.22 million
Net Margins-10.90%
Return on Equity-12.91%
Return on Assets-7.41%

Miscellaneous

Employees980
Outstanding Shares211,040,000

Incyte (NASDAQ:INCY) Frequently Asked Questions

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

How were Incyte's earnings last quarter?

Incyte Corporation (NASDAQ:INCY) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.06 by $0.11. The biopharmaceutical company earned $381.50 million during the quarter, compared to analyst estimates of $360.34 million. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. Incyte's revenue for the quarter was up 41.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.19 earnings per share. View Incyte's Earnings History.

When will Incyte make its next earnings announcement?

Incyte is scheduled to release their next quarterly earnings announcement on Tuesday, February, 13th 2018. View Earnings Estimates for Incyte.

Where is Incyte's stock going? Where will Incyte's stock price be in 2017?

22 brokerages have issued 1-year target prices for Incyte's stock. Their forecasts range from $106.00 to $174.00. On average, they anticipate Incyte's share price to reach $143.65 in the next year. View Analyst Ratings for Incyte.

What are Wall Street analysts saying about Incyte stock?

Here are some recent quotes from research analysts about Incyte stock:

  • 1. Cowen Inc analysts commented, "Over the weekend Incyte presented multiple datasets from a Phase I/II trial of." (6/5/2017)
  • 2. Instinet analysts commented, "Incyte has been incrementally expanding the opportunity for its JAK franchise in oncology and autoimmune. We anticipate near-term upside from novel JAK combos, formulations, and applications in oncology and autoimmune disease. These under-recognized programs represent $25/sh of our target price and, in our view, offer lower-risk opportunities vs. epacadostat." (3/1/2017)
  • 3. Jefferies Group LLC analysts commented, "Solid, unsurprising Valentine's Day 4Q report, with good Jakafi metrics and increasing depth from the maturing pipeline building towards broad, more diversified long-term growth opportunities. We continue to see upside potential in 2017 supported by continued Jakafi execution, IDO data/progress, and bari launch enthusiasm, with scarcity value likely continuing to drive M&A speculation. Adjust tgt to $140 from $136." (2/15/2017)

Who are some of Incyte's key competitors?

Who are Incyte's key executives?

Incyte's management team includes the folowing people:

  • Herve Hoppenot, Chairman of the Board, President, Chief Executive Officer (Age 57)
  • David W. Gryska, Chief Financial Officer, Executive Vice President (Age 61)
  • Reid M. Huber, Executive Vice President, Chief Scientific Officer (Age 45)
  • Eric H. Siegel, Executive Vice President, General Counsel (Age 52)
  • Paula J. Swain, Executive Vice President - Human Resources (Age 59)
  • Barry P. Flannelly, Executive Vice President and General Manager , US (Age 59)
  • Vijay Iyengar, Executive Vice President, Global Strategy and Corporate Development` (Age 44)
  • Wenqing Yao Ph.D., Executive Vice President, Head of Discovery Chemistry (Age 54)
  • Steven H. Stein M.D., Vice President and Chief Medical Officer (Age 50)
  • Julian C. Baker, Lead Independent Director (Age 50)

Who owns Incyte stock?

Incyte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Capital International Investors (3.08%), Bank of New York Mellon Corp (0.79%), Jennison Associates LLC (0.77%), Manning & Napier Advisors LLC (0.51%), Pictet Asset Management Ltd. (0.51%) and American Century Companies Inc. (0.51%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Julian Baker, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Richard S Levy and Steven H Stein. View Institutional Ownership Trends for Incyte.

Who sold Incyte stock? Who is selling Incyte stock?

Incyte's stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Victory Capital Management Inc., Alyeska Investment Group L.P., Frontier Capital Management Co. LLC, KBC Group NV, Neuberger Berman Group LLC, First Trust Advisors LP and Bank of New York Mellon Corp. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, David W Gryska, Eric H Siegel, Herve Hoppenot, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber and Steven H Stein. View Insider Buying and Selling for Incyte.

Who bought Incyte stock? Who is buying Incyte stock?

Incyte's stock was purchased by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Old Mutual Global Investors UK Ltd., Jennison Associates LLC, Pictet Asset Management Ltd., Point72 Asset Management L.P., Capital Bank & Trust Co, Teacher Retirement System of Texas and Capital International Investors. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, Jean Jacques Bienaime and Julian Baker. View Insider Buying and Selling for Incyte.

How do I buy Incyte stock?

Shares of Incyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Incyte's stock price today?

One share of Incyte stock can currently be purchased for approximately $95.97.

How big of a company is Incyte?

Incyte has a market capitalization of $20.70 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $104.22 million in net income (profit) each year or ($0.80) on an earnings per share basis. Incyte employs 980 workers across the globe.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]


MarketBeat Community Rating for Incyte (INCY)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  838 (Vote Outperform)
Underperform Votes:  280 (Vote Underperform)
Total Votes:  1,118
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Incyte (NASDAQ:INCY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.782.832.832.87
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
18 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
19 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
19 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $142.29$144.90$141.10$137.95
Price Target Upside: 49.15% upside27.95% upside17.80% upside15.89% upside

Incyte (NASDAQ:INCY) Consensus Price Target History

Price Target History for Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017Deutsche BankInitiated CoverageHold$106.00MediumView Rating Details
12/12/2017Raymond James FinancialReiterated RatingBuyMediumView Rating Details
12/5/2017CowenReiterated RatingBuyLowView Rating Details
11/21/2017Royal Bank of CanadaLower Price TargetSector Perform -> Sector Perform$136.00 -> $120.00N/AView Rating Details
10/31/2017OppenheimerSet Price TargetHold$135.00N/AView Rating Details
10/31/2017BMO Capital MarketsBoost Price TargetOutperform$162.00 -> $166.00N/AView Rating Details
10/31/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
10/6/2017Goldman Sachs GroupInitiated CoverageBuy$160.00N/AView Rating Details
10/6/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
9/13/2017ArgusReiterated RatingBuy$150.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$135.00MediumView Rating Details
8/2/2017BarclaysReiterated RatingOverweight$180.00 -> $165.00LowView Rating Details
7/16/2017Credit Suisse GroupSet Price TargetBuy$152.00LowView Rating Details
6/28/2017GabelliReiterated RatingBuy$174.00MediumView Rating Details
5/31/2017CIBCBoost Price TargetOutperform$125.00 -> $135.00LowView Rating Details
5/19/2017Morgan StanleyReiterated RatingOverweight$142.00MediumView Rating Details
4/19/2017SunTrust BanksLower Price TargetBuy$160.00 -> $145.00LowView Rating Details
4/17/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Neutral$124.00MediumView Rating Details
3/21/2017William BlairInitiated CoverageOutperformLowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$148.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
1/18/2017JMP SecuritiesReiterated RatingOutperform$130.00N/AView Rating Details
11/20/2016Leerink SwannReiterated RatingOutperform$101.00 -> $115.00N/AView Rating Details
6/6/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
1/31/2016Bank of AmericaReiterated RatingBuy$145.00 -> $87.00N/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Incyte (NASDAQ:INCY) Earnings History and Estimates Chart

Earnings by Quarter for Incyte (NASDAQ:INCY)

Incyte (NASDAQ INCY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018$0.01N/AView Earnings Details
10/31/2017Q3 2017$0.06$0.17$360.34 million$381.50 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.05)($0.06)$318.45 million$326.40 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.97)($0.96)$359.19 million$384.08 millionViewListenView Earnings Details
2/14/2017Q416$0.14$0.05$324.90 million$326.00 millionViewListenView Earnings Details
11/1/2016Q316($0.04)$0.11$260.98 million$269.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.02)$0.18$236.91 million$208.00 millionViewN/AView Earnings Details
5/9/2016Q116$0.29$0.12$266.38 million$263.00 millionViewN/AView Earnings Details
2/11/2016Q415$0.09$0.29$223.54 million$243.88 millionViewListenView Earnings Details
11/3/2015Q315($0.41)($0.22)$179.30 million$187.70 millionViewN/AView Earnings Details
8/4/2015Q215($0.11)($0.04)$153.27 million$162.98 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.11)$155.21 million$159.30 millionViewListenView Earnings Details
2/12/2015Q414($0.14)($0.22)$138.37 million$106.00 millionViewListenView Earnings Details
10/30/2014Q3$0.02$0.33$149.92 million$198.15 millionViewListenView Earnings Details
7/31/2014Q214($0.09)($0.22)$140.72 million$99.58 millionViewListenView Earnings Details
5/1/2014Q114($0.19)($0.21)$97.70 million$89.80 millionViewListenView Earnings Details
2/12/2014Q413($0.10)($0.15)$98.04 million$97.10 millionViewListenView Earnings Details
10/31/2013Q313($0.13)($0.14)$81.40 million$85.10 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.08$0.05$114.34 million$101.70 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.12)$68.16 million$71.10 millionViewListenView Earnings Details
2/14/2013Q4 2012($0.02)$0.14$92.03 million$113.80 millionViewListenView Earnings Details
11/1/2012Q312($0.21)($0.17)$60.61 million$60.50 millionViewN/AView Earnings Details
8/2/2012($0.02)$0.03ViewN/AView Earnings Details
4/26/2012($0.48)($0.36)ViewN/AView Earnings Details
2/15/2012($0.40)($0.44)ViewN/AView Earnings Details
10/27/2011($0.43)($0.42)ViewN/AView Earnings Details
7/28/2011($0.36)($0.41)ViewN/AView Earnings Details
5/3/2011($0.32)($0.21)ViewN/AView Earnings Details
2/10/2011$0.19$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Incyte (NASDAQ:INCY) Earnings Estimates

2017 EPS Consensus Estimate: ($0.60)
2018 EPS Consensus Estimate: $0.19
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.01)($0.82)($0.93)
Q2 20175($0.08)$0.61$0.28
Q3 20176($0.08)$0.32$0.08
Q4 20176($0.59)$0.22($0.03)
Q1 20181($0.21)($0.21)($0.21)
Q2 20182($0.06)$0.04($0.01)
Q3 20182$0.16$0.47$0.32
Q4 20182$0.08$0.10$0.09
Q2 20191$0.65$0.65$0.65
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Incyte (NASDAQ:INCY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Incyte (NASDAQ INCY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.70%
Institutional Ownership Percentage: 90.86%
Insider Trades by Quarter for Incyte (NASDAQ:INCY)
Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Incyte (NASDAQ INCY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Reid M HuberEVPSell696$98.01$68,214.96View SEC Filing  
11/16/2017Paul A FriedmanDirectorSell28,507$105.24$3,000,076.68View SEC Filing  
11/2/2017David W GryskaInsiderSell3,915$105.63$413,541.45View SEC Filing  
9/18/2017Herve HoppenotPresidentSell70,502$119.45$8,421,463.90View SEC Filing  
9/14/2017Barry P FlannellyEVPSell714$124.25$88,714.50View SEC Filing  
9/8/2017Bros. Advisors Lp BakerDirectorBuy100,000$132.00$13,200,000.00View SEC Filing  
9/5/2017Paul TrowerInsiderSell3,000$138.41$415,230.00View SEC Filing  
9/1/2017Eric H SiegelEVPSell1,820$137.40$250,068.00View SEC Filing  
8/31/2017Paula J SwainEVPSell20,000$140.00$2,800,000.00View SEC Filing  
8/29/2017Steven H SteinEVPSell2,111$125.00$263,875.00View SEC Filing  
8/4/2017Paul TrowerInsiderSell3,000$125.25$375,750.00View SEC Filing  
8/1/2017Eric H SiegelEVPSell1,820$132.92$241,914.40View SEC Filing  
7/20/2017Steven H SteinEVPSell6,485$131.09$850,118.65View SEC Filing  
7/5/2017Paul TrowerInsiderSell3,000$126.18$378,540.00View SEC Filing  
7/3/2017Eric H SiegelEVPSell1,820$126.20$229,684.00View SEC Filing  
6/30/2017David W GryskaInsiderSell599$129.74$77,714.26View SEC Filing  
6/20/2017Steven H SteinEVPSell9,883$125.00$1,235,375.00View SEC Filing  
6/12/2017David W GryskaCFOSell16,756$116.60$1,953,749.60View SEC Filing  
6/5/2017Paul TrowerInsiderSell3,000$132.50$397,500.00View SEC Filing  
6/1/2017Eric H SiegelEVPSell1,820$130.00$236,600.00View SEC Filing  
5/31/2017Jean Jacques BienaimeDirectorBuy500$131.80$65,900.00View SEC Filing  
5/15/2017Jean Jacques BienaimeDirectorBuy500$115.00$57,500.00View SEC Filing  
5/8/2017Reid M HuberEVPSell8,577$119.21$1,022,464.17View SEC Filing  
5/1/2017Eric H SiegelEVPSell1,820$124.73$227,008.60View SEC Filing  
4/28/2017Jean Jacques BienaimeDirectorBuy500$124.26$62,130.00View SEC Filing  
4/13/2017Jean Jacques BienaimeDirectorBuy1,000$139.66$139,660.00View SEC Filing  
4/10/2017David W GryskaInsiderSell41,528$138.00$5,730,864.00View SEC Filing  
4/10/2017Eric H SiegelEVPSell4,043$140.18$566,747.74View SEC Filing  
4/7/2017Jean Jacques BienaimeDirectorBuy1,000$139.48$139,480.00View SEC Filing  
4/7/2017Steven H SteinEVPSell32,000$137.88$4,412,160.00View SEC Filing  
3/17/2017Paul A FriedmanDirectorSell50,000$148.72$7,436,000.00View SEC Filing  
1/9/2017Reid M. HuberEVPSell11,739$113.55$1,332,963.45View SEC Filing  
11/9/2016Reid M. HuberEVPSell2,715$109.95$298,514.25View SEC Filing  
10/20/2016Paula J SwainEVPSell10,000$90.00$900,000.00View SEC Filing  
10/7/2016Barry P FlannellyEVPSell24,204$97.00$2,347,788.00View SEC Filing  
9/23/2016Paula J SwainEVPSell20,000$90.00$1,800,000.00View SEC Filing  
8/2/2016Reid M. HuberEVPSell10,000$87.96$879,600.00View SEC Filing  
7/29/2016Paula J SwainEVPSell60,000$90.00$5,400,000.00View SEC Filing  
3/17/2016Julian BakerDirectorBuy800,000$63.98$51,184,000.00View SEC Filing  
2/25/2016Julian BakerDirectorBuy64,290$70.79$4,551,089.10View SEC Filing  
2/16/2016Julian BakerDirectorBuy887,165$69.87$61,986,218.55View SEC Filing  
2/12/2016Julian BakerDirectorBuy2,251,427$63.53$143,033,157.31View SEC Filing  
1/15/2016Paula J. SwainEVPSell13,531$76.96$1,041,345.76View SEC Filing  
1/6/2016Richard S. LevyEVPSell3,937$101.86$401,022.82View SEC Filing  
12/7/2015Richard S. LevyEVPSell3,937$106.18$418,030.66View SEC Filing  
11/18/2015Paul A. FriedmanDirectorSell225,000$113.83$25,611,750.00View SEC Filing  
11/10/2015Eric H. SiegelEVPSell2,222$104.86$232,998.92View SEC Filing  
11/6/2015Richard S. LevyEVPSell3,936$116.51$458,583.36View SEC Filing  
11/3/2015Yao WenqingEVPSell5,786$124.78$721,977.08View SEC Filing  
10/13/2015Eric H. SiegelEVPSell2,222$101.49$225,510.78View SEC Filing  
10/6/2015Richard S. LevyEVPSell3,937$122.29$481,455.73View SEC Filing  
9/21/2015Reid M. HuberEVPSell10,000$124.29$1,242,900.00View SEC Filing  
9/16/2015Eric H. SiegelEVPSell2,222$130.69$290,393.18View SEC Filing  
9/11/2015Richard S LevyEVPSell4,301$130.00$559,130.00View SEC Filing  
9/8/2015Richard S. LevyEVPSell3,937$118.90$468,109.30View SEC Filing  
8/13/2015Eric H SiegelEVPSell2,222$107.69$239,287.18View SEC Filing  
7/15/2015Richard S LevyEVPSell70,217$120.00$8,426,040.00View SEC Filing  
7/14/2015Eric H SiegelEVPSell2,222$113.61$252,441.42View SEC Filing  
7/6/2015Richard S LevyEVPSell3,937$107.00$421,259.00View SEC Filing  
6/23/2015James M DalyEVPSell11,691$108.24$1,265,433.84View SEC Filing  
6/19/2015Richard S LevyEVPSell20,000$108.13$2,162,600.00View SEC Filing  
6/12/2015Eric H SiegelEVPSell2,223$105.31$234,104.13View SEC Filing  
6/8/2015Richard S LevyEVPSell3,937$107.58$423,542.46View SEC Filing  
5/27/2015Paul A FriedmanDirectorSell196,751$107.23$21,097,609.73View SEC Filing  
5/22/2015Paul A FriedmanDirectorSell102,243$108.22$11,064,737.46View SEC Filing  
5/14/2015Eric H SiegelEVPSell2,222$104.99$233,287.78View SEC Filing  
4/23/2015James M DalyEVPSell36,941$107.67$3,977,437.47View SEC Filing  
4/17/2015Yao WenqingEVPSell7,150$102.04$729,586.00View SEC Filing  
4/14/2015Eric H SiegelEVPSell2,222$98.72$219,355.84View SEC Filing  
4/13/2015Yao WenqingEVPSell23,000$95.18$2,189,140.00View SEC Filing  
4/7/2015Yao WenqingEVPSell20,031$90.13$1,805,394.03View SEC Filing  
3/30/2015Laurent ChardonnetVPSell113,776$93.64$10,653,984.64View SEC Filing  
3/30/2015Reid M HuberEVPSell34,263$93.66$3,209,072.58View SEC Filing  
3/12/2015Barry A ArikoDirectorSell80,000$89.27$7,141,600.00View SEC Filing  
3/12/2015Eric H SiegelEVPSell2,222$89.72$199,357.84View SEC Filing  
2/25/2015Eric H SiegelEVPSell13,333$85.00$1,133,305.00View SEC Filing  
2/24/2015James M DalyEVPSell11,112$82.19$913,295.28View SEC Filing  
2/17/2015Paula J SwainEVPSell17,500$76.90$1,345,750.00View SEC Filing  
1/26/2015Eric H SiegelEVPSell13,542$79.85$1,081,328.70View SEC Filing  
1/23/2015James M DalyEVPSell11,109$77.68$862,947.12View SEC Filing  
1/20/2015Paula J SwainEVPSell17,500$74.17$1,297,975.00View SEC Filing  
1/16/2015Richard S LevyEVPSell12,000$73.07$876,840.00View SEC Filing  
1/8/2015Eric H SiegelEVPSell15,626$75.00$1,171,950.00View SEC Filing  
1/6/2015Richard S LevyEVPSell25,000$71.84$1,796,000.00View SEC Filing  
1/5/2015Paula J SwainEVPSell17,500$73.90$1,293,250.00View SEC Filing  
12/23/2014James M DalyEVPSell11,113$74.43$827,140.59View SEC Filing  
12/2/2014Schutter Richard U DeChairmanSell50,000$74.89$3,744,500.00View SEC Filing  
11/6/2014Paul A FriedmanDirectorSell185,653$67.87$12,600,269.11View SEC Filing  
10/23/2014James M DalyEVPSell11,111$53.49$594,327.39View SEC Filing  
9/23/2014James M DalyEVPSell11,111$47.65$529,439.15View SEC Filing  
9/16/2014Richard S LevyEVPSell8,000$47.58$380,640.00View SEC Filing  
8/18/2014Richard S LevyEVPSell8,000$51.97$415,760.00View SEC Filing  
7/23/2014James M DalyEVPSell11,111$48.54$539,327.94View SEC Filing  
7/16/2014Richard S LevyEVPSell8,000$48.15$385,200.00View SEC Filing  
6/23/2014James M DalyEVPSell11,111$56.03$622,549.33View SEC Filing  
6/16/2014Richard S LevyEVPSell8,000$53.88$431,040.00View SEC Filing  
6/5/2014David C HastingsCFOSell200,000$52.73$10,546,000.00View SEC Filing  
5/23/2014James M DalyEVPSell11,111$48.48$538,661.28View SEC Filing  
5/16/2014Richard LevyEVPSell8,000$50.68$405,440.00View SEC Filing  
5/2/2014Laurent ChardonnetVPSell34,000$51.55$1,752,700.00View SEC Filing  
4/23/2014James DalyEVPSell30,555$47.71$1,457,779.05View SEC Filing  
2/20/2014Paul FriedmanDirectorSell33,354$63.51$2,118,312.54View SEC Filing  
2/19/2014Paul FriedmanDirectorSell771,182$65.65$50,628,098.30View SEC Filing  
2/19/2014Schutter Richard DeChairmanSell50,000$65.53$3,276,500.00View SEC Filing  
2/18/2014David HastingsCFOSell275,000$65.86$18,111,500.00View SEC Filing  
9/10/2013Paul A FriedmanCEOSell376,789$37.32$14,061,765.48View SEC Filing  
9/9/2013Laurent ChardonnetVPSell44,834$37.31$1,672,756.54View SEC Filing  
9/6/2013David C HastingsCFOSell100,000$35.16$3,516,000.00View SEC Filing  
9/6/2013Richard S LevyEVPSell25,000$35.28$882,000.00View SEC Filing  
9/5/2013Paula J SwainEVPSell94,444$35.06$3,311,206.64View SEC Filing  
8/19/2013Roy WhitfieldDirectorSell50,000$26.70$1,335,000.00View SEC Filing  
5/17/2013Roy A WhitfieldDirectorSell40,000$23.08$923,200.00View SEC Filing  
5/13/2013Richard S LevyEVPSell55,699$22.30$1,242,087.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Incyte (NASDAQ INCY) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Incyte Corporation (INCY) Will Post Quarterly Sales of $409.49 Million Brokerages Anticipate Incyte Corporation (INCY) Will Post Quarterly Sales of $409.49 Million
www.americanbankingnews.com - December 15 at 6:24 AM
Incyte (INCY) Now Covered by Deutsche BankIncyte (INCY) Now Covered by Deutsche Bank
www.americanbankingnews.com - December 12 at 10:06 PM
Incyte (INCY) Earns Buy Rating from Raymond James FinancialIncyte (INCY) Earns Buy Rating from Raymond James Financial
www.americanbankingnews.com - December 12 at 6:34 PM
Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi - Yahoo FinanceIncyte (INCY) Reports Phase III Follow-Up Data for Jakafi - Yahoo Finance
finance.yahoo.com - December 12 at 7:39 AM
Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi - Business Wire (press release)Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi - Business Wire (press release)
www.businesswire.com - December 10 at 3:25 PM
Incyte (INCY) Downgraded by TheStreetIncyte (INCY) Downgraded by TheStreet
www.americanbankingnews.com - December 8 at 4:40 PM
Annual Gala Honoring MPN Heroes® - Business Wire (press release)Annual Gala Honoring MPN Heroes® - Business Wire (press release)
www.businesswire.com - December 8 at 3:22 PM
Incyte (INCY) Rating Reiterated by CowenIncyte (INCY) Rating Reiterated by Cowen
www.americanbankingnews.com - December 6 at 2:56 PM
MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte - GlobeNewswire (press release)MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte - GlobeNewswire (press release)
globenewswire.com - December 6 at 7:55 AM
Incyte Corporation (INCY) EVP Sells $68,214.96 in StockIncyte Corporation (INCY) EVP Sells $68,214.96 in Stock
www.americanbankingnews.com - December 5 at 7:34 PM
Incyte is Now Oversold (INCY)Incyte is Now Oversold (INCY)
www.nasdaq.com - December 4 at 3:22 PM
Incyte: Depressed Valuation With Catalysts Coming - Seeking AlphaIncyte: Depressed Valuation With Catalysts Coming - Seeking Alpha
seekingalpha.com - December 3 at 7:34 AM
Contrasting Incyte (INCY) and Roka Bioscience (ROKA)Contrasting Incyte (INCY) and Roka Bioscience (ROKA)
www.americanbankingnews.com - December 3 at 5:42 AM
Head to Head Comparison: Incyte (INCY) and Its CompetitorsHead to Head Comparison: Incyte (INCY) and Its Competitors
www.americanbankingnews.com - December 1 at 3:32 AM
Incyte Corporation (INCY) Receives Consensus Recommendation of "Buy" from BrokeragesIncyte Corporation (INCY) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 30 at 2:18 PM
Incyte Corporation (INCY) Expected to Post FY2020 Earnings of $4.30 Per ShareIncyte Corporation (INCY) Expected to Post FY2020 Earnings of $4.30 Per Share
www.americanbankingnews.com - November 27 at 9:52 PM
$411.33 Million in Sales Expected for Incyte Corporation (INCY) This Quarter$411.33 Million in Sales Expected for Incyte Corporation (INCY) This Quarter
www.americanbankingnews.com - November 27 at 2:28 AM
FY2021 EPS Estimates for Incyte Corporation (INCY) Lowered by GabelliFY2021 EPS Estimates for Incyte Corporation (INCY) Lowered by Gabelli
www.americanbankingnews.com - November 23 at 10:08 PM
Incyte Co. (INCY) PT Lowered to $120.00 at Royal Bank Of CanadaIncyte Co. (INCY) PT Lowered to $120.00 at Royal Bank Of Canada
www.americanbankingnews.com - November 21 at 8:58 PM
Incyte Corporation 2017 Q3 - Results - Earnings Call SlidesIncyte Corporation 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 21 at 12:41 AM
Paul A. Friedman Sells 28,507 Shares of Incyte Corporation (INCY) StockPaul A. Friedman Sells 28,507 Shares of Incyte Corporation (INCY) Stock
www.americanbankingnews.com - November 20 at 7:36 PM
Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi - Business Wire (press release)Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi - Business Wire (press release)
www.businesswire.com - November 17 at 6:50 AM
Analyzing Incyte Corporation (INCY) and Its RivalsAnalyzing Incyte Corporation (INCY) and Its Rivals
www.americanbankingnews.com - November 17 at 1:24 AM
Incyte Corporation (INCY) and Abeona Therapeutics (ABEO) Head-To-Head ComparisonIncyte Corporation (INCY) and Abeona Therapeutics (ABEO) Head-To-Head Comparison
www.americanbankingnews.com - November 14 at 3:40 PM
$411.23 Million in Sales Expected for Incyte Corporation (INCY) This Quarter$411.23 Million in Sales Expected for Incyte Corporation (INCY) This Quarter
www.americanbankingnews.com - November 9 at 4:52 PM
Lightning Round: Jim Cramer Gives His Opinion On Incyte, Apache And More - BenzingaLightning Round: Jim Cramer Gives His Opinion On Incyte, Apache And More - Benzinga
www.benzinga.com - November 8 at 10:25 AM
Cramers lightning round: Dont give up on Incyte - CNBC.com - CNBCCramer's lightning round: Don't give up on Incyte - CNBC.com - CNBC
www.cnbc.com - November 8 at 10:25 AM
Zacks: Analysts Anticipate Incyte Corporation (INCY) Will Announce Earnings of -$0.37 Per ShareZacks: Analysts Anticipate Incyte Corporation (INCY) Will Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - November 7 at 1:26 AM
Vapid Earnings Visibility Restrict Incyte (INCY) RatingVapid Earnings Visibility Restrict Incyte (INCY) Rating
investorplace.com - November 6 at 8:43 PM
Incyte Corporation to Post Q4 2017 Earnings of ($0.59) Per Share, William Blair Forecasts (INCY)Incyte Corporation to Post Q4 2017 Earnings of ($0.59) Per Share, William Blair Forecasts (INCY)
www.americanbankingnews.com - November 6 at 8:40 AM
FY2017 Earnings Forecast for Incyte Corporation Issued By Gabelli (INCY)FY2017 Earnings Forecast for Incyte Corporation Issued By Gabelli (INCY)
www.americanbankingnews.com - November 6 at 4:38 AM
Incyte Corp. :INCY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Incyte Corp. :INCY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 4 at 2:18 AM
Incyte Corporation (INCY) & Its Peers Critical AnalysisIncyte Corporation (INCY) & Its Peers Critical Analysis
www.americanbankingnews.com - November 3 at 9:14 PM
David W. Gryska Sells 3,915 Shares of Incyte Corporation (INCY) StockDavid W. Gryska Sells 3,915 Shares of Incyte Corporation (INCY) Stock
www.americanbankingnews.com - November 3 at 5:42 PM
Oversold Conditions For IncyteOversold Conditions For Incyte
www.forbes.com - November 3 at 9:56 AM
FY2021 EPS Estimates for Incyte Corporation (INCY) Cut by AnalystFY2021 EPS Estimates for Incyte Corporation (INCY) Cut by Analyst
www.americanbankingnews.com - November 2 at 5:34 PM
Oppenheimer Holdings Research Analysts Lift Earnings Estimates for Incyte Corporation (INCY)Oppenheimer Holdings Research Analysts Lift Earnings Estimates for Incyte Corporation (INCY)
www.americanbankingnews.com - November 2 at 5:34 PM
Q4 2018 Earnings Estimate for Incyte Corporation Issued By William Blair (INCY)Q4 2018 Earnings Estimate for Incyte Corporation Issued By William Blair (INCY)
www.americanbankingnews.com - November 2 at 4:40 PM
Q2 2018 Earnings Forecast for Incyte Corporation (INCY) Issued By SunTrust BanksQ2 2018 Earnings Forecast for Incyte Corporation (INCY) Issued By SunTrust Banks
www.americanbankingnews.com - November 2 at 2:33 PM
BRIEF-Incyte says Q3 earnings per share $0.17BRIEF-Incyte says Q3 earnings per share $0.17
www.businessinsider.com - November 2 at 2:19 AM
Incyte (INCY) Says More Than 30 Abstracts Highlighting Data from its Portfolio Accepted for Presentation at ASHIncyte (INCY) Says More Than 30 Abstracts Highlighting Data from its Portfolio Accepted for Presentation at ASH
www.streetinsider.com - November 2 at 2:19 AM
More Than 30 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 59 th Annual ASH MeetingMore Than 30 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 59 th Annual ASH Meeting
www.businesswire.com - November 2 at 2:19 AM
Heres What Was Intriguing About Incytes Q3 ReportHere's What Was Intriguing About Incyte's Q3 Report
www.benzinga.com - November 2 at 2:19 AM
Buy the dip in Incyte - Credit SuisseBuy the dip in Incyte - Credit Suisse
seekingalpha.com - November 1 at 3:50 PM
Incyte (INCY) Q3 2017 Results - Earnings Call Transcript | Seeking ... - Seeking AlphaIncyte (INCY) Q3 2017 Results - Earnings Call Transcript | Seeking ... - Seeking Alpha
seekingalpha.com - October 31 at 10:35 PM
Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early ... - Business Wire (press release)Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early ... - Business Wire (press release)
www.businesswire.com - October 31 at 10:35 PM
Incyte Corporation (INCY) PT Raised to $166.00Incyte Corporation (INCY) PT Raised to $166.00
www.americanbankingnews.com - October 31 at 7:18 PM
Incyte Corporation (INCY) Given Buy Rating at J P Morgan Chase & CoIncyte Corporation (INCY) Given Buy Rating at J P Morgan Chase & Co
www.americanbankingnews.com - October 31 at 3:25 PM
Incyte Corporation (INCY) Releases Quarterly  Earnings Results, Beats Expectations By $0.11 EPSIncyte Corporation (INCY) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS
www.americanbankingnews.com - October 31 at 8:56 AM
Incyte Corporation (INCY) Appoints Jacqualyn A. Fouse, Ph.D to BoardIncyte Corporation (INCY) Appoints Jacqualyn A. Fouse, Ph.D to Board
www.streetinsider.com - October 31 at 3:14 AM

SEC Filings

Incyte (NASDAQ:INCY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Incyte (NASDAQ:INCY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Incyte (NASDAQ INCY) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.